154 related articles for article (PubMed ID: 35195909)
1. The prognostic significance of further genotyping H3G34 diffuse hemispheric gliomas.
Vuong HG; Le HT; Dunn IF
Cancer; 2022 May; 128(10):1907-1912. PubMed ID: 35195909
[TBL] [Abstract][Full Text] [Related]
2. High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?
Hu W; Duan H; Zhong S; Zeng J; Mou Y
J Transl Med; 2022 Feb; 20(1):64. PubMed ID: 35109850
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults.
Picart T; Barritault M; Poncet D; Berner LP; Izquierdo C; Tabouret E; Figarella-Branger D; Idbaïh A; Bielle F; Bourg V; Vandenbos FB; Moyal EC; Uro-Coste E; Guyotat J; Honnorat J; Gabut M; Meyronet D; Ducray F
Neurooncol Adv; 2021; 3(1):vdab061. PubMed ID: 34056608
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
[TBL] [Abstract][Full Text] [Related]
5. H3G34-mutant diffuse hemispheric glioma with osseous metastases: a case report and literature review.
Yu N; Lee HS; Raslan OA; Jin LW; Aboud O
CNS Oncol; 2023 Jun; 12(2):CNS95. PubMed ID: 36919796
[No Abstract] [Full Text] [Related]
6. Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: A case series and systematic review.
Kurokawa R; Baba A; Kurokawa M; Pinarbasi ES; Makise N; Ota Y; Kim J; Srinivasan A; Moritani T
J Neuroimaging; 2022 Jan; 32(1):17-27. PubMed ID: 34632671
[TBL] [Abstract][Full Text] [Related]
7. Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas.
Gianno F; Antonelli M; Di Dio T; Minasi S; Donofrio V; Buccoliero AM; Gardiman MP; Pollo B; Diomedi Camassei F; Rossi S; Novello M; Giangaspero F; Arcella A; Gessi M; Buttarelli FR
Am J Surg Pathol; 2021 Feb; 45(2):200-204. PubMed ID: 33428336
[TBL] [Abstract][Full Text] [Related]
8. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients.
Vuong HG; Le HT; Ngo TNM; Fung KM; Battiste JD; McNall-Knapp R; Dunn IF
J Neurooncol; 2021 Dec; 155(3):225-234. PubMed ID: 34796414
[TBL] [Abstract][Full Text] [Related]
9. H3G34-Mutant Gliomas-A Review of Molecular Pathogenesis and Therapeutic Options.
Nguyen AV; Soto JM; Gonzalez SM; Murillo J; Trumble ER; Shan FY; Huang JH
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509641
[TBL] [Abstract][Full Text] [Related]
10. H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.
Lavrador JP; Reisz Z; Sibtain N; Rajwani K; Baig Mirza A; Vergani F; Gullan R; Bhangoo R; Ashkan K; Bleil C; Zebian B; Clark B; Laxton R; King A; Bodi I; Al-Saraj S
Acta Neurochir (Wien); 2023 Jun; 165(6):1615-1633. PubMed ID: 36929449
[TBL] [Abstract][Full Text] [Related]
11. MRI characteristics of H3 G34-mutant diffuse hemispheric gliomas and possible differentiation from IDH-wild-type glioblastomas in adolescents and young adults.
Shao H; Gong J; Su X; Chen N; Li S; Yang X; Zhang S; Huang Z; Hu W; Gong Q; Liu Y; Yue Q
J Neurosurg Pediatr; 2024 Mar; 33(3):236-244. PubMed ID: 38157540
[TBL] [Abstract][Full Text] [Related]
12. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors.
Crowell C; Mata-Mbemba D; Bennett J; Matheson K; Mackley M; Perreault S; Erker C
Neurooncol Adv; 2022; 4(1):vdac133. PubMed ID: 36105387
[TBL] [Abstract][Full Text] [Related]
14. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction.
Fang J; Huang Y; Mao G; Yang S; Rennert G; Gu L; Li H; Li GM
Proc Natl Acad Sci U S A; 2018 Sep; 115(38):9598-9603. PubMed ID: 30181289
[TBL] [Abstract][Full Text] [Related]
15. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
16. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
17. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis.
Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S
AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic pleomorphic xanthoastrocytoma associated with an H3G34 mutation: a case report with review of literature.
Sasaki S; Tomomasa R; Nobusawa S; Hirato J; Uchiyama T; Boku E; Miyasaka T; Hirose T; Ohbayashi C
Brain Tumor Pathol; 2019 Oct; 36(4):169-173. PubMed ID: 31350684
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
Yoshimoto K; Hatae R; Sangatsuda Y; Suzuki SO; Hata N; Akagi Y; Kuga D; Hideki M; Yamashita K; Togao O; Hiwatashi A; Iwaki T; Mizoguchi M; Iihara K
Brain Tumor Pathol; 2017 Jul; 34(3):103-112. PubMed ID: 28447171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]